Drug Delivery and Therapy Strategies for Osteoporosis Intervention

With the advent of the aging society, osteoporosis (OP) risk increases yearly. Currently, the clinical usage of anti-OP drugs is challenged by recurrent side effects and poor patient compliance, regardless of oral, intravenous, or subcutaneous administration. Properly using a drug delivery system or formulation strategy can achieve targeted drug delivery to the bone, diminish side effects, improve bioavailability, and prolong the in vivo residence time, thus effectively curing osteoporosis. This review expounds on the pathogenesis of OP and the clinical medicaments used for OP intervention, proposes the design approach for anti-OP drug delivery, emphatically discusses emerging novel anti-OP drug delivery systems, and enumerates anti-OP preparations under clinical investigation. Our findings may contribute to engineering anti-OP drug delivery and OP-targeting therapy.

Automated summary

With the increase in the aging population, there is a growing risk of osteoporosis. The use of anti-osteoporosis drugs in clinical settings is currently hindered by recurring side effects and poor patient compliance, regardless of the method of administration. Utilizing drug delivery systems or formulation strategies can target drug delivery to the bones, reduce side effects, improve bioavailability, and prolong the effectiveness of treatment. This review focuses on the pathogenesis of osteoporosis, clinical medications used for intervention, the design approach for drug delivery, and emerging novel drug delivery systems for osteoporosis treatment. These findings contribute to the engineering of anti-osteoporosis drug delivery and targeted therapy.